{"disease":{"id":"fanconi-anemia-complementation-group-a","name":"fanconi anemia complementation group a"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04042831","title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT04437771","title":"Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Rocket Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04248439","title":"Gene Therapy for Fanconi Anemia, Complementation Group A","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"Rocket Pharmaceuticals Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}